COSMAX’s skin microbiome research is the first of its kind to be published in the International Scientific Journal

  • The work, published in Nature Communications Biology, reveals the link between skin microorganisms and aging
  • New product launches expected include anti-aging, hair loss prevention and oral care products
  • The results of six years of research secure the “super gap” in skin microbiome research

Seoul, South Korea, April 19, 2021 / PRNewswire / – Global Cosmetics Research, Development, and ODM Company COSMAX (CEO) Lee Byung-man) and the Gwangju Institute for Science and Technology (GIST) were the first in the world to uncover the link between the skin microbiome and skin aging.

COSMAX announced that its PhD thesis entitled “Spermidine-Induced Skin Structure Restoration and Barrier Functionality by Skin Microbiomes” has been published by Nature Communications Biology.

In 2015, COSMAX discovered that a person’s skin flora directly regulates the skin, and the company began research related to anti-aging. After discovering that the number of microorganisms living on the skin decreased with age, they hypothesized that they were an important key to antiaging and started performing genetic analysis.

They named a newly discovered microorganism “Strain-COXMAX” and, together with GIST, carried out an entire genome analysis that can be used to trace the role of entire genomes in order to uncover the anti-aging functions of the microorganism.

The results of the analysis showed that the microorganism influences the aging process by regulating various metabolic functions of the skin. It has also been discovered that spermidine, produced during the metabolic process, has a direct impact on anti-aging of the skin. In addition, spermidine was shown to be effective in improving skin moisture, elasticity and anti-aging by activating collagenesis and lipid secretion.

“The discovery of the correlation mechanism between the skin microbiome and aging is an accomplishment achieved through six years of hard work,” said the director of the R&I center Myeong Park-Sam. “The technological super gap will be used in the next generation of anti-aging cosmetics and biomaterials on the world market.”

COXMAX is expected to expand the application of the skin microbiome to various products. Such products include::

  • Anti-aging cosmetics
  • Anti-hair loss shampoo
  • Mouthwash and
  • functional foods for oral health.

“The publication of the skin microbiome technology in a global scientific journal provides an opportunity to announce the R&D status of K-beauty,” said COSMAX CEO Lee Byung-Man. “It will be at the heart of the global health and beauty market, using innovative materials to create products that don’t already exist in the world.”

In 2019, COSMAX launched the world’s first anti-aging cosmetic using Strain-COXMAX, a culture medium containing beneficial skin bacteria. By securing more than 20 beneficial microorganisms, the company has become a leader in the skin microbiome market.
< i>taken at 100,000 times magnification using SEM (scanning electron microscope)>

The microbiome, a portfolio of “microbes” and “biome”, describes the microorganisms living in the human body and their genomes. The microbiome is so large that it makes up 1 to 3 percent of the body’s mass and contains over 100 times more genes than our own genome. The microbiome known as the “second genome” could be viewed as an ecosystem that contains a lot of information about the body.

Because the microbiome regulates immune functions and makes various types of metabolites, it is known to affect obesity, diabetes, atopic dermatitis, cancer, and autoimmune diseases. As a result, research into the precise role of the microbiome in disease and aging has increased dramatically and related markets have grown rapidly.

Since its inception in 2015, Genome & Company has grown to become a global leader in microbiome immuno-oncology. It is focused on developing the next waves of innovative therapeutics in immuno-oncology through various modalities of microbiomes and novel target immune checkpoint inhibitors.


Related Articles